Back to results
US 2026/0015404 A1Published application
Bi-specific targeted chimeric antigen receptor t cells
AssigneeCity of Hope
InventorsXiuli Wang, Stephen J. Forman, Don J. Diamond
Life of this patent
Estimating the term…
Abstract
T cells expressing a chimeric antigen receptor and a T cell receptor specific for CMV (bi-specific T cells) are described as a methods for using such cells in immunotherapy. In the immunotherapy methods, the recipient can be exposed to a CMV vaccine in order to expand and/or stimulate the be-specific T cells.
Claims8
A method comprising:
- (a) providing PBMC from a cytomegalovirus (CMV) seropositive human donor;
- (b) exposing the PBMC to at least one CMV antigen to provide a population of CMV antigen exposed PBMC;
- (c) enriching the population of CMV antigen exposed PBMC for cells expressing interferon gamma (IFN-y) to produce an enriched cell population;
- and
- (d) transducing the enriched cell population with a nucleic acid molecule encoding a chimeric antigen receptor (CAR) to produce a population of cells comprising cells that express the CAR and bind a CMV antigen, wherein the method does not include treatment to stimulate CD3.
2 more elements
Dependencies are inferred from the claim text.